NCT00069316 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Jennett B, Bond M
Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480-4.
McDowell I, Kristjansson B, Hill GB, Hébert R
Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol. 1997 Apr;50(4):377-83.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J
Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7.

A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)

Details for clinical trial NCT00069316

Clinical trial NCT00069316 - References